366 related articles for article (PubMed ID: 38203429)
1. Re-Arranging the Puzzle between the Amyloid-Beta and Tau Pathology: An APP-Centric Approach.
Haut F; Argyrousi EK; Arancio O
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203429
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
3. Role of Amyloid-β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade.
Gulisano W; Maugeri D; Baltrons MA; Fà M; Amato A; Palmeri A; D'Adamio L; Grassi C; Devanand DP; Honig LS; Puzzo D; Arancio O
J Alzheimers Dis; 2018; 64(s1):S611-S631. PubMed ID: 29865055
[TBL] [Abstract][Full Text] [Related]
4. Key Peptides and Proteins in Alzheimer's Disease.
Penke B; Bogár F; Paragi G; Gera J; Fülöp L
Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
[TBL] [Abstract][Full Text] [Related]
5. Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice.
Chen Y; Zhao S; Fan Z; Li Z; Zhu Y; Shen T; Li K; Yan Y; Tian J; Liu Z; Zhang B
Alzheimers Res Ther; 2021 Feb; 13(1):40. PubMed ID: 33563332
[TBL] [Abstract][Full Text] [Related]
6. Synaptic Mitochondria: An Early Target of Amyloid-β and Tau in Alzheimer's Disease.
Torres AK; Jara C; Park-Kang HS; Polanco CM; Tapia D; Alarcón F; de la Peña A; Llanquinao J; Vargas-Mardones G; Indo JA; Inestrosa NC; Tapia-Rojas C
J Alzheimers Dis; 2021; 84(4):1391-1414. PubMed ID: 34719499
[TBL] [Abstract][Full Text] [Related]
7. An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis.
Caselli RJ; Knopman DS; Bu G
Alzheimers Dement; 2020 Nov; 16(11):1582-1590. PubMed ID: 32588983
[TBL] [Abstract][Full Text] [Related]
8. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.
Kirouac L; Rajic AJ; Cribbs DH; Padmanabhan J
eNeuro; 2017; 4(2):. PubMed ID: 28374012
[TBL] [Abstract][Full Text] [Related]
9. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
10. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
[TBL] [Abstract][Full Text] [Related]
11. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.
Manczak M; Reddy PH
Hum Mol Genet; 2012 Dec; 21(23):5131-46. PubMed ID: 22926141
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Potential of Therapeutic Agents Targeted towards Mitigating the Events Associated with Amyloid-β Cascade in Alzheimer's Disease.
Behl T; Kaur I; Fratila O; Brata R; Bungau S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050199
[TBL] [Abstract][Full Text] [Related]
13. APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.
Barbero-Camps E; Fernández A; Martínez L; Fernández-Checa JC; Colell A
Hum Mol Genet; 2013 Sep; 22(17):3460-76. PubMed ID: 23648430
[TBL] [Abstract][Full Text] [Related]
14. [Alzheimer disease: cellular and molecular aspects].
Octave JN
Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in the Modeling of Alzheimer's Disease.
Sasaguri H; Hashimoto S; Watamura N; Sato K; Takamura R; Nagata K; Tsubuki S; Ohshima T; Yoshiki A; Sato K; Kumita W; Sasaki E; Kitazume S; Nilsson P; Winblad B; Saito T; Iwata N; Saido TC
Front Neurosci; 2022; 16():807473. PubMed ID: 35431779
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-β, tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues.
Majdi A; Sadigh-Eteghad S; Rahigh Aghsan S; Farajdokht F; Vatandoust SM; Namvaran A; Mahmoudi J
Rev Neurosci; 2020 May; 31(4):391-413. PubMed ID: 32017704
[TBL] [Abstract][Full Text] [Related]
17. Are N- and C-terminally truncated Aβ species key pathological triggers in Alzheimer's disease?
Dunys J; Valverde A; Checler F
J Biol Chem; 2018 Oct; 293(40):15419-15428. PubMed ID: 30143530
[TBL] [Abstract][Full Text] [Related]
18. βAPP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimer's Disease.
Audrain M; Souchet B; Alves S; Fol R; Viode A; Haddjeri A; Tada S; Orefice NS; Joséphine C; Bemelmans AP; Delzescaux T; Déglon N; Hantraye P; Akwa Y; Becher F; Billard JM; Potier B; Dutar P; Cartier N; Braudeau J
Cereb Cortex; 2018 Nov; 28(11):3976-3993. PubMed ID: 29048465
[TBL] [Abstract][Full Text] [Related]
19. Understanding the Amyloid Hypothesis in Alzheimer's Disease.
Paroni G; Bisceglia P; Seripa D
J Alzheimers Dis; 2019; 68(2):493-510. PubMed ID: 30883346
[TBL] [Abstract][Full Text] [Related]
20. Aβ and Tau Interact with Metal Ions, Lipid Membranes and Peptide-Based Amyloid Inhibitors: Are These Common Features Relevant in Alzheimer's Disease?
Di Natale G; Sabatino G; Sciacca MFM; Tosto R; Milardi D; Pappalardo G
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
